NCT06099886CompletedPhase 1
Repurposing Lithium for Parkinson's Disease
Repurposing Lithium as a Disease-modifying Therapy in Parkinson's Disease: A Phase I Trial
Source: ClinicalTrials.gov · Last updated 13 May 2026
Brief summary (registry, in English)
This study will examine the effects of lithium aspartate 30-45mg/day on MRI biomarkers and blood-based therapeutic targets among 15 early-stage Parkinson's disease patients.
- Status (registry)
- Completed
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 15 (actual)
- First submitted
- 30 Aug 2023
- Start date
- 12 Oct 2023
- Primary completion date
- 6 Dec 2024
- Lead sponsor
- State University of New York at Buffalo
- Diseases
- Parkinson disease
- NCT number
- NCT06099886
What you commit to
- Study type: Interventional · Phase 1
- Participants enrolled: 15
- From 12 Oct 2023 to the primary completion date, 6 Dec 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Have PD for \>4 years or does not have PD. Have abnormal normal thyroid and renal function at the screening visit. Have previous exposure to lithium therapy. Have history of brain surgery. Have hx of brain imaging findings suggesting another neurological condition besides PD.
- Have use of tobacco or THC products within the past year. Have PD medication adjustments within 30 days or needs PD medication adjustments in the investigator's opinion.
Other illness
- Have psychiatric or diuretic medication adjustments within the last 60 days or is anticipated to need changes over next 24 weeks.
- Have active medical or psychiatric condition that may interfere with study procedures in the investigator's opinion.
Who the study is looking for
- Have PD for \<4 years diagnosed by a movement disorder specialist. Have normal thyroid and renal function at the screening visit. Have no previous exposure to lithium therapy. Have no history of brain surgery. Have no hx of brain imaging findings suggesting another neurological condition besides PD.
- Have no use of tobacco or THC products for \>1 year. Have stable PD medications for \>30 days without current need for adjustments in the investigator's opinion.
- Have stable psychiatric and diuretic medications for \>60 days with no anticipated need for changes for at least 24 weeks.
- Have no active medical or psychiatric condition that may interfere with study procedures in the investigator's opinion.
Age in the registry: 45 years to 80 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University at Buffalo Coordinator of this site? Confirm its status | Williamsville | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.